Capricorn Fund Managers Ltd Takes $4.87 Million Position in Kenvue Inc. $KVUE

Capricorn Fund Managers Ltd bought a new position in Kenvue Inc. (NYSE:KVUE) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 282,485 shares of the company’s stock, valued at approximately $4,873,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of KVUE. American Century Companies Inc. increased its holdings in Kenvue by 22.4% in the 3rd quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock valued at $601,267,000 after acquiring an additional 6,781,640 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Kenvue by 13.5% during the third quarter. Dimensional Fund Advisors LP now owns 23,127,234 shares of the company’s stock valued at $375,377,000 after purchasing an additional 2,747,952 shares in the last quarter. Van ECK Associates Corp grew its position in shares of Kenvue by 101.3% during the third quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company’s stock valued at $298,008,000 after purchasing an additional 9,240,434 shares in the last quarter. Amundi increased its holdings in shares of Kenvue by 21.6% in the third quarter. Amundi now owns 17,645,761 shares of the company’s stock worth $277,012,000 after purchasing an additional 3,135,871 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of Kenvue by 2.3% in the third quarter. Legal & General Group Plc now owns 14,785,925 shares of the company’s stock worth $239,976,000 after purchasing an additional 332,870 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

KVUE opened at $17.16 on Monday. The business has a fifty day moving average of $17.98 and a 200 day moving average of $17.07. The stock has a market cap of $32.90 billion, a P/E ratio of 22.29, a PEG ratio of 3.89 and a beta of 0.61. The company has a quick ratio of 0.68, a current ratio of 0.96 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $25.17.

Kenvue (NYSE:KVUE) last released its earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.05. The business had revenue of $3.78 billion for the quarter, compared to analyst estimates of $3.68 billion. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The business’s revenue was up 3.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.26 earnings per share. As a group, sell-side analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th were issued a dividend of $0.2075 per share. The ex-dividend date was Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a yield of 4.8%. Kenvue’s dividend payout ratio (DPR) is presently 107.79%.

Analyst Ratings Changes

KVUE has been the subject of a number of research reports. Argus raised Kenvue to a “hold” rating in a research note on Friday, March 6th. Canaccord Genuity Group upped their price objective on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a report on Wednesday, February 18th. Weiss Ratings reissued a “hold (c-)” rating on shares of Kenvue in a report on Friday, January 9th. UBS Group upped their price target on shares of Kenvue from $17.00 to $19.00 and gave the company a “neutral” rating in a research note on Wednesday, February 18th. Finally, Citigroup lifted their price objective on shares of Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 18th. Three research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $19.58.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.